Involving Production Or Treatment Of Antibody Patents (Class 436/547)
-
Patent number: 8137991Abstract: The present invention pertains to methods of inhibiting angiogenesis in an individual in need thereof comprising administering to the individual an agent that inhibits one or more CEP protein adducts wherein the angiogenesis is the result of oxidative peptide modification of polyunsaturated fatty acids (PUFA) in the individual, and administration of the agent inhibits angiogenesis in the individual. In one embodiment, the invention is directed to methods of inhibiting ocular angiogenesis in an individual in need thereof comprising administering to the individual an agent that inhibits the angiogenic activity of one or more CEP protein adducts wherein administration of the. agent inhibits ocular angiogenesis in the individual.Type: GrantFiled: July 23, 2007Date of Patent: March 20, 2012Assignees: The Cleveland Clinic Foundation, Case Western Reserve UniversityInventors: John W. Crabb, Robert G. Salomon, Bela Anand-Apte, Quteba Ebrahem, Kutralanathan Reganathan
-
Patent number: 8133744Abstract: A method of making antibodies to a selected part P of an immunoglobulin molecule ZP, Z comprising the non-selected part of ZP, P being the selected part of ZP which comprises a hidden epitope of the light chain, said method comprises tolerizing the source of antibodies, by administering to the source a compound containing the non-selected part Z or a part of Z and administering antibodies to the non-selected part Z or a part of Z; wherein these administered antibodies are specific to an Fc region of ZP; and immunizing the source of antibodies with part of ZP having the selected part P exposed; and wherein Z comprises non-hidden epitopes of said immunoglobulin molecule, and wherein said compound containing the non-selected part of said molecule comprises a whole immunoglobulin, and wherein immunizing the source of antibodies with part of ZP comprises immunizing with free light chain.Type: GrantFiled: October 31, 1996Date of Patent: March 13, 2012Assignee: The Binding Site Group LimitedInventor: Arthur Randell Bradwell
-
Publication number: 20120045851Abstract: Labels are disclosed capable of forming a covalent or non-covalent bond with a target molecule, particularly a biological molecule. The structure of these labels may consist of a dye covalently bound by one or more carbons on its chemical structure to one or more [FUNC] group(s), and optionally one or more [SOL] group(s). The structure of these labels allow selection of dyes from a wide variety of different excitation and emission wavelengths and allow easy functionalization of the dye without appreciably altering its spectral characteristics or its solubility characteristics.Type: ApplicationFiled: September 9, 2011Publication date: February 23, 2012Applicant: LABORATOIRES SYNTH-INNOVEInventors: Francois SCHERNINSKI, Vincent Guyon, Marie-Noelle Rager
-
Patent number: 8110663Abstract: The present invention provides a new sensitive direct sandwich assay for determining the presence of COMP in a clinical sample. Two monoclonal antibodies directed against separate antigenic determinants of the COMP molecules are used in the assay. The invention also relates to three particularly advantageous monoclonal antibodies per se that are directed against human COMP. Cell cultures manufacturing these antibodies have been deposited according to the Budapest Treaty at Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH, and have been assigned accesion numbers DSM ACC2406, DSM ACC2408 and DSM ACC2418, respectively. A diagnostic kit comprising at least two of these monoclonal antibodies also constitute a part of the present invention.Type: GrantFiled: April 27, 2010Date of Patent: February 7, 2012Assignee: AnaMar ABInventor: Dick Heinegård
-
Patent number: 8067247Abstract: The invention relates to the use a BD16 and/or BB18 anti-CD100 antibody or of a chimeric or humanized or human form thereof, or a fragment thereof, for the therapy or diagnosis of a central nervous system disorder, more particularly a myelin disorder or a disease that affects oligodendrocytes, such as multiple sclerosis or HTLV-1 associated myelopathy or peripheral myelinating cells.Type: GrantFiled: February 2, 2004Date of Patent: November 29, 2011Assignee: Institut National de la Sante Et de la Recherche Medicale (INSERM)Inventors: Marie-Françoise Belin, Pascale Giraudon, Laurence Boumsell, Armand Bensussan
-
Patent number: 8062881Abstract: Hydrophobic polymer surfaces whose level of protein binding is less than about 50-80 ng/cm2 are achieved by: (1) applying a coating solution composed of a solvent and a non-ionic surfactant having a HLB number of less than 5 to the surface; and (2) drying the surface to remove the solvent and thereby bring the surfactant into direct contact with the hydrophobic polymer. The combination of a low HLB number and the drying step have been found to produce low binding surfaces which can withstand multiple washes with water and/or protein-containing solutions Alternatively, the low binding surfaces can be produced by applying the non-ionic surfactant to the mold surfaces which contact molten polymer and form the polymer into a desired shape, e.g., into a multi-well plate, a pipette tip, or the like. Further, the low binding surfaces may be produced by incorporating non-soluble, non-ionic surfactants having an HLB number of less than or equal to 10 into a polymer blend prior to molding the article.Type: GrantFiled: July 8, 2010Date of Patent: November 22, 2011Assignee: Corning IncorporatedInventors: Dana Craig Bookbinder, Edward John Fewkes, Jr., James Arthur Griffin, Frances M. Smith, David L. Tennent
-
Patent number: 8034338Abstract: The invention refers to an immunogenic recombinant antibody designed for immunization of primates comprising at least a part of a murine IgG2a subtype amino acid sequence and a mammalian glycosylation.Type: GrantFiled: April 16, 2004Date of Patent: October 11, 2011Assignee: Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-AGInventors: Hans Loibner, Gottfried Himmler, Günter Waxenecker, Manfred Schuster, Thomas Putz
-
Patent number: 7989219Abstract: A capturing molecule having an association containing a plurality of polypeptide chains that specifically bind to different sites of a target substance, characterized in that each of the polypeptide chains has a domain having a hypervariable loop structure at a binding site binding to the target substance and an association portion for forming the association, and the polypeptide chains are associated via the association portions present in the polypeptide chains.Type: GrantFiled: May 30, 2006Date of Patent: August 2, 2011Assignee: Canon Kabushiki KaishaInventors: Hidenori Shiotsuka, Satoru Hatakeyama, Tsuyoshi Nomoto, Masaru Kaieda, Junta Yamamichi
-
Patent number: 7977104Abstract: The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.Type: GrantFiled: September 27, 2006Date of Patent: July 12, 2011Assignee: The Trustees of Columbia University in the City of New YorkInventors: John F. O'Connor, Galina I. Kovalevskaya, Steven Birken
-
Patent number: 7939282Abstract: Compositions and methods for detecting sepsis by contacting a subject-derived sample with a ligand that binds to GRK and determining the concentration of GRK in the sample. An increase in the concentration of GRK compared to that of a normal, healthy control sample indicates that the subject from which the sample is obtained is suffering from or at risk of developing sepsis.Type: GrantFiled: October 20, 2005Date of Patent: May 10, 2011Assignee: Rhode Island HospitalInventors: Loren D. Fast, Yow-Pin Lim
-
Patent number: 7939344Abstract: New applications for the use of distinguishable particulate labels available in a variety of hues and sized in the submicron range are described. These applications include profiling of cellular components, obtaining secretion patterns, identifying a multiplicity of components in chromatographic or electrophoretic techniques and identification of desired immunoglobulin secreting cells.Type: GrantFiled: August 8, 2008Date of Patent: May 10, 2011Assignee: Trellis Bioscience, Inc.Inventors: Lawrence M. Kauvar, Remy Cromer, William D. Harriman, Ellen J. Collarini
-
Patent number: 7919257Abstract: The present invention provides combinations of specific binding proteins, such as immunoglobulins, that are designed to be true combinations, essentially all components of the combination being functional and compatible with each other. The invention further provides a method for producing a composition comprising at least two different proteinaceous molecules comprising paired variable regions, the at least two proteinaceous molecules having different binding specificities, comprising paired variable regions, at least two proteinaceous molecules having different binding specificities, comprising contacting at least three different variable regions under conditions allowing for pairing of variable regions and harvesting essentially all proteinaceous molecules having binding specificities resulting from the pairing.Type: GrantFiled: November 30, 2005Date of Patent: April 5, 2011Assignee: Merus Biopharmaceuticals, B.V.i.o.Inventors: Hendricus Renerus Jacobus Mattheus Hoogenboom, Ton Logtenberg
-
Patent number: 7919255Abstract: A means of measuring and monitoring skeletal growth rate using a plasma analyte, amino-terminal C-type natriuretic peptide (NT-CNP). Plasma NT-CNP concentrations reflect the potential for further growth of the immature skeleton. Measurement of plasma NT-CNP in a subject, when related to the mean of an appropriate age and gender matched set of control subjects, provides an index of the severity of a growth disorder not otherwise available and facilitates diagnosis in children with undetected osteo-chondrodysplasias or other intrinsic disorders of the growth plate. The invention also provides a means of detecting and monitoring potentially harmful effects of drugs and other factors on skeletal growth long before they are evident using current methods in clinical practice.Type: GrantFiled: June 17, 2004Date of Patent: April 5, 2011Assignee: Otago Innovation LimitedInventors: Timothy Charles Ramsey Prickett, Eric Arnold Espiner, Arthur Mark Richards, Timothy Grant Yandle, Michael Gary Nicholls
-
Patent number: 7906297Abstract: The invention discloses two novel phosphorylation sites in human ATR kinase, serine 428 (Ser428) and serine 2317 (Ser2317) respectively, and provides reagents, including antibodies and AQUA peptides, that selectively bind to and/or detect ATR only when phosphorylated at one or more of these respective sites, but do not bind to ATR when not phosphorylated at these respective sites. Also provided are methods for determining the phosphorylation of ATR kinase in a biological sample, by using a detectable reagent that binds to ATR only when phosphorylated at Ser428 and/or Ser2317. Kits comprising the ATR (Ser428, Ser2317)-specific reagents of the invention are also provided.Type: GrantFiled: July 17, 2006Date of Patent: March 15, 2011Assignee: Cell Signaling Technology, Inc.Inventors: Mark Livingstone, Hong Ruan, Robert Polakiewicz
-
Patent number: 7893220Abstract: Novel conjugates of busulfan and novel busulfan immunogens derived from ?-substituted derivatives of busulfan and antibodies generated by these busulfan linked immunogens are useful in immunoassays for the quantification and monitoring of busulfan in biological fluids.Type: GrantFiled: July 9, 2008Date of Patent: February 22, 2011Assignee: Saladax Biomedical Inc.Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Shu He
-
Patent number: 7875465Abstract: A capturing molecule having not less than two domains specifically binding to different sites of a target substance, wherein the not less than two domains comprise (1) a first domain having a hypervariable loop structure at a binding site to the target substance, and (2) a second domain having no hypervariable loop structure at a binding site to the target substance.Type: GrantFiled: May 29, 2006Date of Patent: January 25, 2011Assignee: Canon Kabushiki KaishaInventors: Hidenori Shiotsuka, Satoru Hatakeyama, Tsuyoshi Nomoto, Masaru Kaieda, Junta Yamamichi
-
Publication number: 20100330577Abstract: This disclosure relates to methods for identifying an antibody, a target molecule, or an agent by analyzing the immunoglobulin repertoire sequence data in a sample and by determining the most dominant VH and VL chains present in said sample, as well as materials used therewith.Type: ApplicationFiled: February 11, 2009Publication date: December 30, 2010Applicant: MORPHOSYS AGInventor: Markus Enzelberger
-
Patent number: 7858751Abstract: It is intended to provide a specific peptide fragment of LYVE-1 which can serve as an epitope of a lymphatic vessel-specific antibody, and an antibody recognizing the above peptide fragment. A peptide fragment comprising an amino acid sequence: Ser Lys Lys Thr Asp Lys Asn Pro Glu Glu Ser Lys, or the peptide fragment in which an amino acid as a linker to the C-terminal or the N-terminal thereof is added.Type: GrantFiled: January 10, 2008Date of Patent: December 28, 2010Assignee: Oriental Yeast Co., Ltd.Inventors: Kinji Ito, Toshiharu Ishii, Yuri Fukasawa
-
Patent number: 7858757Abstract: The present invention concerns a monoclonal antibody and corresponding hybridoma cells and antigens suitable for isolating fetal cells from maternal blood. The monoclonal antibody reacts with a surface antigen present on fetal red blood cells including their nucleated precursor cells, but not with surface antigens on adult erythroid cell.Type: GrantFiled: March 31, 2005Date of Patent: December 28, 2010Assignee: Adnagen AGInventors: Christiane Hollmann, Silke Zimmermann, Stefan Stachelhaus, Winfried Albert
-
Patent number: 7838245Abstract: The present invention relates to the use of protachykinin and/or fragments thereof that can be isolated from body fluids, tissues or other bioiological samples and therefore, serves as a marker peptide for medical diagnosis of diseases/disorders of the central nervous system, including Alzheimer's disease, Parkinson's disease, depression and/or conditions of pain, neurological, endocrinological, cerebral, muscular, local, systemic, chronic, inflammatory diseases, infectious diseases comprising bacterial and viral infections, meningitis, sepsis, Crohn's disease, colitis ulcerosa, sickle cell anemia, ischemia, amyotrophic lateral sclerosis, arthritis comprising rheumatoid arthritis, bronchitis, hyperalgesia, asthma, intoxication comprising bacterial intoxication, immunological disorders, poly/-trauma comprising cranio-cerebral trauma, tumors/cancer, stroke, stress, atopis dermatitis, HIV, Huntington's disease, burns, schizophrenia, Hirschsprung's disease, allergies, familial dysautononmia (Riley Day syndrome),Type: GrantFiled: April 20, 2005Date of Patent: November 23, 2010Assignee: Sphingotec GmbHInventors: Andreas Bergmann, Andrea Ernst
-
Patent number: 7833731Abstract: A protein utilizing an anti-gold antibody and a gold-binding side which is a part of the anti-gold antibody is constructed. This protein is capable of specifically binding to gold. This protein or a complex protein containing such a protein can be used for the detection of a target substance.Type: GrantFiled: March 31, 2005Date of Patent: November 16, 2010Assignee: Canon Kabushiki KaishaInventors: Hidenori Shiotsuka, Takeshi Imamura, Izumi Kumagai
-
Patent number: 7811832Abstract: Provided are methods and compositions for maintaining the viability of photoreceptor cells following retinal detachment. The viability of photoreceptor cells can be preserved by administering an apoptosis inhibitor to a mammal having an eye with retinal detachment. The apoptosis inhibitor maintains the viability of the photoreceptor cells until such time that the retina becomes reattached to the underlying retinal pigment epithelium and choroid. The treatment minimizes the loss of vision, which otherwise may occur as a result of retinal detachment.Type: GrantFiled: July 16, 2004Date of Patent: October 12, 2010Assignee: Massachusetts Eye and Ear InfirmaryInventors: David Zacks, Joan W. Miller
-
Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
Patent number: 7790861Abstract: The invention relates to novel nucleic acids encoding a mammalian PCADM-1 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, prostate cancer. The invention further relates to methods of detecting and treating prostate cancer, comprising modulating or detecting PCADM-1 expression and/or production and activity of PCADM-1 polypeptide. Further, the invention relates to novel assays for the identification of DNA-binding proteins and the double-stranded oligonucleotide sequences that specifically bind with them. Finally, the invention relates to DNAZYMs or DNA enzymes which specifically bind PCADM-1 mRNA to inhibit PCADM-1 gene expression and thereby destroy tumor cells and tumor tissue.Type: GrantFiled: May 7, 2002Date of Patent: September 7, 2010Assignee: Philadelphia Health and Education CorporationInventors: Mark Stearns, Youji Hu, Min Wang -
Patent number: 7776572Abstract: Hydrophobic polymer surfaces whose level of protein binding is less than about 50-80 ng/cm2 are achieved by: (1) applying a coating solution composed of a solvent and a non-ionic surfactant having a HLB number of less than 5 to the surface; and (2) drying the surface to remove the solvent and thereby bring the surfactant into direct contact with the hydrophobic polymer. The combination of a low HLB number and the drying step have been found to produce low binding surfaces which can withstand multiple washes with water and/or protein-containing solutions Alternatively, the low binding surfaces can be produced by applying the non-ionic surfactant to the mold surfaces which contact molten polymer and form the polymer into a desired shape, e.g., into a multi-well plate, a pipette tip, or the like. Further, the low binding surfaces may be produced by incorporating non-soluble, non-ionic surfactants having an HLB number of less than or equal to 10 into a polymer blend prior to molding the article.Type: GrantFiled: February 16, 2007Date of Patent: August 17, 2010Assignee: Corning IncorporatedInventors: Dana Craig Bookbinder, Edward John Fewkes, Jr., James Arthur Griffin, Frances M. Smith, David L. Tennent
-
Patent number: 7759466Abstract: Monoclonal antibody that specifically binds to alpha-amylase and is useful for detecting weather damage (i.e. pre-harvest sprouting) in cereal grain.Type: GrantFiled: June 1, 2006Date of Patent: July 20, 2010Assignee: Bayer CropScience AGInventor: John Howard Skerritt
-
Patent number: 7749772Abstract: Antibodies having specific binding for the parent THC (?9-THC) and its major metabolites are provided which present a significant increase in sensitivity of immunoassays such as lateral flow immunoassays and ELISA for THC. The present invention also provides a rabbit hybridoma producing the antibody as a monoclonal antibody, a recombinant antibody, further molecularly engineered recombinant antibodies against parent ?9-THC and its metabolites and cell lines producing the recombinant antibodies. The invention also provides applications of the antibody in immunoassays, particularly lateral flow immunoassays, specifically applications in detecting THC in body fluids, particularly saliva, and kits for determining the presence of THC.Type: GrantFiled: June 29, 2006Date of Patent: July 6, 2010Assignee: Varian, Inc.Inventor: Daniel Wang
-
Patent number: 7745230Abstract: The present invention provides isolated polypeptides having an amino acid sequence having at least 70% identity to SEQ ID NO:20, wherein the polypeptide has ER-?36 activity. The invention further provides methods for identifying agents that bind to such polypeptides, methods for detecting such polypeptides, and methods for altering the activity of such polypeptides. Also provided are antibodies that specifically bind to an amino acid sequence depicted at SEQ ID NO:1, or an immunogenic fragment thereof, and methods for making and using such antibodies.Type: GrantFiled: March 10, 2005Date of Patent: June 29, 2010Assignee: Creighton UniversityInventor: Zhao Yi Wang
-
Patent number: 7741443Abstract: The present invention provides a human C-type lectin, binding molecules that specifically bind to the human C-type lectin, nucleic acid molecules encoding the binding molecules or the human C-type lectin, compositions comprising the binding molecules or the human C-type lectin and methods of identifying or producing the binding molecules. The human C-type lectin is specifically expressed on myeloid cells and binding molecules capable of specifically binding to the human C-type lectin can be used in the diagnosis, prevention and/or treatment of neoplastic disorders and diseases.Type: GrantFiled: December 22, 2005Date of Patent: June 22, 2010Assignee: Crucell Holland B.V.Inventors: Sonja van den Oudenrijn, Marja van Meijer, Adrianus Q. Bakker, Alexander Berthold Hendrik Bakker
-
Patent number: 7732156Abstract: The present invention provides a new sensitive direct sandwich assay for determining the presence of COMP in a clinical sample. Two monoclonal antibodies directed against separate antigenic determinants of the COMP molecules are used in the assay. The invention also relates to three particularly advantageous monoclonal antibodies per se that are directed against human COMP. Cell cultures manufacturing these antibodies have been deposited according to the Budapest Treaty at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, and have been assigned accession numbers DSM ACC2406, DSM ACC2408 and DSM ACC2418, respectively. A diagnostic kit comprising at least two of these monoclonal antibodies also constitute a part of the present invention.Type: GrantFiled: November 9, 2006Date of Patent: June 8, 2010Assignee: Anamar Medical ABInventor: Dick Heinegard
-
Publication number: 20100105150Abstract: A method of determining the presence, amount or concentration of at least one autoantibody that reacts with neutrophil gelatinase-associated lipocalin (NGAL), alone or in further combination with a method of determining the concentration of NGAL, which methods can further comprise diagnosing, prognosticating, or assessing the efficacy of a therapeutic/prophylactic treatment of a patient and, optionally, modifying the therapeutic/prophylactic treatment of the patient as needed to improve efficacy; a kit comprising at least one component for assaying a test sample for at least one autoantibody that reacts with NGAL and instructions for assaying; a method of isolating an autoantibody that reacts with NGAL; an isolated autoantibody that reacts with NGAL; and a method for determining the reliability of an NGAL assay result.Type: ApplicationFiled: October 24, 2008Publication date: April 29, 2010Applicant: ABBOTT LABORATORIESInventors: Maciej Adamczyk, Roy Jeffrey Brashear, Phillip G. Mattingly
-
Patent number: 7700299Abstract: The invention is related to a method of predicting the response to a treatment with a HER inhibitor in a patient comprising the steps of assessing a biomarker or a combination of biomarkers selected from the group consisting of amphiregulin, an epidermal growth factor, a transforming growth factor alpha, and a HER2 biomarker in a biological sample from the patient and predicting the response to the treatment with the HER inhibitor in the patient by evaluating the results of the first step. Further uses and methods wherein these markers are used are disclosed.Type: GrantFiled: May 19, 2006Date of Patent: April 20, 2010Assignee: Hoffmann-La Roche Inc.Inventors: Joachim Moecks, Andreas Strauss, Gerhard Zugmaier
-
Patent number: 7670855Abstract: The present invention features peptides of a PorB polypeptide, which PorB peptides are useful in production of antibodies that bind the full-length PorB polypeptide and as a therapeutic agent. In specific embodiments the invention features a composition comprising one or more PorB peptides (other than a full-length PorB polypeptide), which peptides contain at least one epitope that can elicit Chlamydia-neutralizing antibodies. The invention also features methods for induction of a protective immune response against infection by Chlamydia and Chlamydiophila.Type: GrantFiled: June 27, 2007Date of Patent: March 2, 2010Assignee: The Regents of the University of CaliforniaInventors: Richard S. Stephens, Diane Kawa
-
Patent number: 7662642Abstract: Disclosed are epitope-containing heat shock fusion proteins, DNA constructs encoding such fusion proteins, and methods of use. More specifically, disclosed are ubiquitin fusion proteins comprising ubiquitin fused to a plurality of identical or non-identical epitopes at specified locations.Type: GrantFiled: October 7, 2003Date of Patent: February 16, 2010Assignee: Wellstat BioCatalysis, LLCInventors: John H. Kenten, Alfonso Tramontano, Aprile L. Pilon, Gerald L. Lohnas, Steven F. Roberts
-
Patent number: 7662928Abstract: Antibodies to heavy chain of human FcRn are provided which function as non-competitive inhibitors of IgG binding to FcRn. The antibodies may be polyclonal, monoclonal, chimeric or humanized, or antigen binding fragments thereof. These antibodies are useful for reducing the concentration of pathogenic IgGs in individuals and therefore used as a therapeutic tool in autoimmune and alloimmune conditions.Type: GrantFiled: December 6, 2006Date of Patent: February 16, 2010Assignee: The Research Foundation of State University of New YorkInventors: Joseph P. Balthasar, Ryan J. Hansen, Feng Jin
-
Publication number: 20100015637Abstract: The present disclosure relates to glycosylated and deglycosylated human PlGF-1, methods of using the glycosylated and deglycosylated human PlGF-1, antibodies that bind to human PlGF-1, methods of using the antibodies and human PlGF-1 immunoassays and kits.Type: ApplicationFiled: June 16, 2009Publication date: January 21, 2010Applicant: ABBOTT LABORATORIESInventors: Susan E. Brophy, Lianli Chi, Saul A. Datwyler, David J. Hawksworth, Don M. Laird, Sharmila Manoj, Mary S. Pinkus, Dominick L. Pucci, Carol S. Ramsay, David C. Sogin, Bailin Tu, Joan D. Tyner, Lowell J Tyner, Zhiguang Yu, Robert N. Ziemann
-
Patent number: 7615383Abstract: The invention concerns agonist anti-trkC monoclonal antibodies which mimic certain biological activities of NT-3, the native ligand of trkC. The invention further concerns the use of such antibodies in the prevention and/or treatment of cellular degeneration, including nerve cell damage associated with acute nervous cell system injury and chronic neurodegenerative diseases, including peripheral neuropathy.Type: GrantFiled: October 16, 2006Date of Patent: November 10, 2009Assignee: Genentech, Inc.Inventors: Brigitte Devaux, Jo-Anne Hongo, Leonard G. Presta, David L. Shelton
-
Patent number: 7601506Abstract: The invention provides a simple method for diagnosing a non-symptomatic or symptomatic human or animal with transmissible spongiform encephalopathy.Type: GrantFiled: July 28, 2006Date of Patent: October 13, 2009Assignee: IDEXX Laboratories, Inc.Inventors: Roy Jackman, Linda Ann Terry, Sally Jane Everest
-
Patent number: 7598351Abstract: The anti-19P2 ligand monoclonal antibodies of the invention (in particular P2L-1Ca) have very high binding ability and can neutralize the arachidonic acid metabolite releasing activity of the 19P2 ligand. Therefore, they can be used, among others, as diagnostic, prophylactic and/or therapeutic agents for various diseases caused by some or other abnormality in the pituitary function modulating activity (e.g. prolactin secretion promoting activity), central nervous system modulating activity and pancreatic function modulating activity, among others, supposedly possessed by the 19P2 ligand.Type: GrantFiled: December 3, 2004Date of Patent: October 6, 2009Assignee: Takeda Pharmaceutical Company LimitedInventors: Hirokazu Matsumoto, Chieko Kitada, Shuji Hinuma
-
Patent number: 7579157Abstract: Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing the antibodies, and uses for the antibodies are disclosed. Antibodies against IGF-IR are implicated in antitumor therapy.Type: GrantFiled: July 8, 2004Date of Patent: August 25, 2009Assignee: Hoffmann-La Roche Inc.Inventors: Yvo Graus, Erhard Kopetzki, Klaus-Peter Kuenkele, Olaf Mundigl, Paul Parren, Frank Rebers, Ralf Schumacher, Jan van de Winkel, Martine Vriesema-van Vugt
-
Patent number: 7575873Abstract: The invention provides a novel human Mab Fab, cloned by phage display, and its use in diagnostic and therapeutic methods. In particular the invention provides a method for analyzing the OxLDL components of atherosclerotic plaques in vivo and a means to determine their relative pathology. As the method is based on a human Fab rather than a mouse Mab, the progress or regression of the disease may be monitored over time. The antibody may also be used for the analysis of surgical or serum samples ex vivo for the presence of OxLDL. The antibody may also be used to target therapeutic agents to the site of atherosclerotic plaques or may have use as a therapeutic agent itself.Type: GrantFiled: November 12, 2003Date of Patent: August 18, 2009Assignee: The Regents of the University of CaliforniaInventors: Joseph L. Witztum, Sotirios Tsimikas, Wulf Palinski
-
Publication number: 20090196872Abstract: Human, humanized and chimeric monoclonal antibodies that bind to influenza M2 protein. A human monoclonal antibody that binds to influenza M2 protein having different amino acid sequences. The antibodies are useful for, among other things, treatment, diagnostics, purifying and isolating M2 or influenza virus, and identifying the presence of M2 or influenza virus in a sample or a subject.Type: ApplicationFiled: December 5, 2005Publication date: August 6, 2009Applicant: KIRIN BEER KABUSHIKI KAISHAInventors: Shinichiro Kato, Rongfang Wang
-
Patent number: 7531314Abstract: A method of producing antibodies comprising the step of encoding a peptide sequence from a Domain I perlecan splice variant, wherein the peptide sequence is used to produce anti-peptide antibodies.Type: GrantFiled: August 4, 2006Date of Patent: May 12, 2009Assignee: University of WashingtonInventors: Grace A. Maresh, Alan D. Snow
-
Patent number: 7527939Abstract: A specific and sensitive in vitro ELISA assay and diagnostic test kit is disclosed for determining levels of NT-proBNP protein in a variety of bodily fluids, non-limiting examples of which are blood, serum, plasma, urine and the like. The NT-proBNP ELISA assay test employs the sandwich ELISA technique to measure circulating NT-proBNP in human plasma. In order to obtain antibodies with specific binding properties for targeted amino acid sequences within human proBNP, recombinant human proBNP (or rhproBNP) was expressed and purified for use as an immunogen. Polyclonal antibodies (PAb) to specific amino acid sequences were subsequently purified from goat serum by sequential affinity purification. Monoclonal antibodies were raised against specific polypeptides. Recombinant human NT-proBNP (or rhNT-proBNP) was expressed and purified in order to obtain material for use in calibration of a quantitative method for measurement of human NT-proBNP.Type: GrantFiled: March 13, 2006Date of Patent: May 5, 2009Assignee: Nanogen, Inc.Inventors: Michelle Davey, George Jackowski, Peter Kupchak, Eric Stanton
-
Publication number: 20090087842Abstract: The present invention enabled the detection and quantification of CAST, which is localized to synapses and tightly bound to the cytomatrix, and of the mRNA encoding the CAST. Furthermore, it was revealed that CAST functions as a protein scaffold for localizing RIM1 to synapses, contributing as a molecular basis for active zone formation.Type: ApplicationFiled: October 31, 2007Publication date: April 2, 2009Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Toshihisa Ohtsuka, Etsuko Rikitsu, Marie Inoue, Eiji Inoue
-
Patent number: 7511123Abstract: Novels immuno-interactive fragments of the (alpha)C portion of a mammalian inhibin alpha subunit are disclosed, together with their variants and derivatives for producing antigen-binding molecules that are interactive with said (alpha)C portion, which are chemically well defined and which can be produced in commercially significant quantities. The antigen-binding molecules of the invention can be used for the detection of a mammalian inhibin and for the treatment and/or prevention of conditions associated with aberrant levels of a mammalian inhibin.Type: GrantFiled: April 18, 2002Date of Patent: March 31, 2009Assignee: Prince Henry's Institute of Medical ResearchInventors: David Mark Milne-Robertson, Peter Gordon Stanton, Nicholas Francis Cahir
-
Patent number: 7511142Abstract: Compositions and methods for electrochemical detection of an analyte comprising a transition metal compound wherein M is a metallic element that can form a coordinate bond to nitrogen; R and R? are coordinated to M at their nitrogen atoms; L is a linking ligand; Z is chlorine or bromine; m can be from 1 to 6 and X is an anion, or combination of anions, that balances the charge m. Also provided are electrochemical tags and methods of detection.Type: GrantFiled: July 28, 2004Date of Patent: March 31, 2009Assignee: Agency for Science, Technology and ResearchInventors: Hong Xie, Zhiqiang Gao
-
Publication number: 20090081225Abstract: A novel class of embryo derived peptides are described (Preimplantation factor) that were generated synthetically and were tested on peripheral blood immune cells and shown to block activated but not basal immunity, inhibiting cell proliferation and creating a TH2 type cytokine bias, in addition PIF enhance endometrial receptivity by increasing adhesion molecules expression. PIF biological activity appears to be exerted by specific binding to inducible receptors present on the several white cell lineages. PIF peptides, which are immune modulators therefore may have diagnostic and non toxic therapeutic applications in improving fertility, reducing pregnancy loss as well may be useful when administered for the treatment of autoimmune diseases and for prevention xenotransplants rejection. Further, polyclonal antibodies against PIF peptides were generated that serve for precise measurements of PIF in biological fluids.Type: ApplicationFiled: October 22, 2004Publication date: March 26, 2009Inventor: Eytan R. Barnea
-
Publication number: 20090075398Abstract: A method of obtaining at least one recombinant antibody with improved affinity for a selected antigen from a family of antibodies which bind the selected antigen comprising: a) obtaining a family of two or more antibodies which bind the same antigen in which the VH CDR3 amino acid sequence of each antibody in the family is the same length and greater than 60% identical at the amino acid level; b) re-pairing the VH region of an antibody obtained in step (a) with the VL region from a different antibody obtained in step (a) to produce a new recombinant antibody; and c) screening the recombinant antibody produced in step (b) and selecting said antibody if it has improved affinity for the selected antigen compared to any one of the antibodies obtained in step (a).Type: ApplicationFiled: April 4, 2006Publication date: March 19, 2009Applicant: UCB PHARMA S.A.Inventor: Alastair David Griffiths Lawson
-
Patent number: 7494782Abstract: A method for determining the concentration of factor VIIa-antithrombin complexes is disclosed which has application to estimating the level of intravascular exposure of tissue factor, assessing patient risk for hypercoagulation or other coagulopathies, and monitoring patients for factor VIIa-antithrombin complexes over time which can reveal changes in risk for hypercoagulation or other coagulopathies and/or effectiveness of anticoagulant therapy. Antibodies suitable for use in an in vitro assay for determining the concentration of factor VIIa-antithrombin complexes and methods for making the same are also disclosed.Type: GrantFiled: July 2, 2002Date of Patent: February 24, 2009Inventor: James H. Morrissey
-
Patent number: 7485438Abstract: Embodiments of the invention generally provide methods and compositions for producing polyvalent antigens. In one aspect, the invention provides a method for producing a cross-linked antigen. In another aspect, the invention provides a method of using cross-linked products as antigens to immunize animals and induce strong immune responses.Type: GrantFiled: August 28, 2002Date of Patent: February 3, 2009Inventor: Szu-Yi Chou